Spinal Versus General Anesthesia in Open Simple Prostatectomy
Effect of Spinal Versus General Anesthesia on Postoperative Bleeding in Patients Undergoing Open Simple Prostatectomy: A Prospective Randomized Controlled Trial
1 other identifier
interventional
80
1 country
1
Brief Summary
Open simple prostatectomy is still performed for selected patients with benign prostatic hyperplasia, particularly in cases with large prostate volume. Postoperative bleeding, hematuria, clot retention, and transfusion requirement are clinically important complications after this procedure. This prospective randomized controlled trial will compare the effects of spinal anesthesia and general anesthesia on postoperative bleeding in patients undergoing open simple prostatectomy. Participants will be randomized into two groups: spinal anesthesia or general anesthesia. Tranexamic acid or any additional hemostatic agent will not be used. Postoperative bleeding will be assessed using hemoglobin and hematocrit changes, transfusion requirement, hematuria, clot retention, need for bladder irrigation, and bleeding-related reintervention. The study aims to determine whether spinal anesthesia is associated with reduced postoperative bleeding compared with general anesthesia in open simple prostatectomy.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Apr 2026
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 29, 2026
CompletedFirst Submitted
Initial submission to the registry
June 8, 2026
CompletedFirst Posted
Study publicly available on registry
June 11, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 15, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
September 15, 2026
June 11, 2026
June 1, 2026
4 months
June 8, 2026
June 8, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Clinically Significant Postoperative Bleeding
Clinically significant postoperative bleeding is defined as the occurrence of at least one of the following events: Requirement for red blood cell transfusion; Hemoglobin decrease ≥2 g/dL accompanied by persistent gross hematuria and/or ongoing bladder irrigation; Clot retention requiring intensified bladder irrigation or endoscopic clot evacuation; Bleeding-related reintervention.
Within 72 hours after surgery
Study Arms (2)
Spinal Anesthesia
ACTIVE COMPARATORParticipants allocated to this arm will receive spinal anesthesia for open simple prostatectomy according to the institutional standard anesthesia protocol.
General Anesthesia
ACTIVE COMPARATORParticipants allocated to this arm will receive general anesthesia for open simple prostatectomy according to the institutional standard anesthesia protocol.
Interventions
Spinal anesthesia will be performed at the L3-4 or L4-5 interspace under aseptic conditions using hyperbaric bupivacaine. Light sedation may be administered when clinically required.
General anesthesia will be induced and maintained according to the institutional standard protocol. Airway management, mechanical ventilation, anesthetic maintenance, antiemetic prophylaxis, and multimodal analgesia will be applied according to routine clinical practice.
Eligibility Criteria
You may qualify if:
- Male patients aged 18 years or older.
- Diagnosis of benign prostatic hyperplasia (BPH).
- Scheduled to undergo open simple prostatectomy.
- American Society of Anesthesiologists (ASA) physical status I-III.
- Ability to provide written informed consent.
You may not qualify if:
- Refusal or inability to provide informed consent.
- Patients scheduled for radical prostatectomy due to prostate cancer.
- Emergency surgery.
- Known coagulation disorders or clinically significant thrombocytopenia.
- Ongoing anticoagulant or antiplatelet therapy that cannot be discontinued according to institutional protocols.
- Contraindication to spinal anesthesia.
- Participation in another interventional clinical trial that may affect study outcomes.
- Administration of tranexamic acid or any additional hemostatic agent during the perioperative period.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Hitit Universitylead
Study Sites (1)
Hitit university
Çorum, Turkey (Türkiye)
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Ozgur Yağan, Professor
Hitit University
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Medical Doctor
Study Record Dates
First Submitted
June 8, 2026
First Posted
June 11, 2026
Study Start
April 29, 2026
Primary Completion (Estimated)
August 15, 2026
Study Completion (Estimated)
September 15, 2026
Last Updated
June 11, 2026
Record last verified: 2026-06
Data Sharing
- IPD Sharing
- Will not share